Alicia Morgans, MD

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Merck
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Dendreon
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Clovis
    Mitigation strategy: 
    Divest
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Janssen
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Genetech
    Mitigation strategy: 
    Divest
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Sanofi
    Mitigation strategy: 
    Divest
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Astellas
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Astra Zeneca
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Bayer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Genetech
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/07/2023

Pages

Return to Advances in ADT: Part II: A Guide for Urologists (2023)